Friday, April 29, 2022 7:43:13 PM
Per today's PR
ANEW MEDICAL, INC., (OTC Pink: LEAS) today announced that Dr. Joseph Sinkule, the CEO and Founder of ANEW MEDICAL INC. (ANEW), will be attending and presenting at The Q2 Investor Summit Group - In-Person. ANEW is focused on completing a late-stage, randomized Phase 3 study of a biosimilar antibody called bevacizumab (Genentech/Roche Avastin™) and early-stage trials of a cutting-edge genetic therapy targeting neurodegenerative diseases - Alzheimer's and Lou Gehrig's disease. Dr. Sinkule, a forty-year biotech veteran, will present the corporate strategy and plans for the Alzheimer's disease program leading to first-in-man clinical trials of the "anti-aging" a-Klotho gene and gene constructs efficiently delivered by an adeno-associated virus (AAV) to the brain and central nervous system.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM